Summary The level of expression of keratinocyte growth factor (KGF) mRNA has been measured in human breast cell lines, purified populations of epithelial cells, myoepithelial cells and fibroblasts from reduction mammoplasty tissue and a panel of 42 breast cancers and 30 non-malignant human breast tissues using a semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) procedure. We found similar levels of KGF mRNA in malignant and non-malignant breast tissues. The study of the amount of KGF mRNA in breast cell lines and purified populations of cells revealed that fibroblasts are the predominant source of KGF with malignant and non-malignant epithelial cells containing very low levels of KGF mRNA. We have examined the distribution of fibroblast growth factor receptor (FGFR)-2-lllb, which is a highaffinity receptor for KGF and find that it is present on malignant and non-malignant epithelial cells. The level of FGFR-2-lllb present on breast cancer cell lines was sufficient for KGF stimulation of breast cancer cell proliferation. Other members of the fibroblast growth factor family have been either not expressed in the human breast (FGF3, FGF4) or have been found at much reduced levels in breast cancer (FGF1, FGF2) and this is the first member of the family to potentially influence the progression of breast cancer through stimulation of cell division.
Fibroblast growth factors (FGFs) comprise a family of nine polypeptide mitogens including acidic FGF (FGF1), basic FGF (FGF2), int-2 (FGF3), hst (FGF4), FGF5, FGF6 and keratinocyte growth factor (KGF or FGF7) (Basilico and Moscatelli, 1992) . Two more recently identified members of the family are androgeninduced growth factor (AIGF, FGF8) and glia-activating factor (GAF, FGF9) (Tanaka et al, 1992; Miyamoto et al, 1993) . KGF differs from the other members by its high specificity for activating epithelial cells (Finch et al, 1989) . It is expressed in cells of mesenchymal origin such as fibroblasts and endothelial cells but not in epithelial cells (Finch et al, 1989; Smola et al 1993) . It therefore seems likely that KGF stimulates epithelial cells in a paracrine manner.
Four genes encoding high-affinity receptors for FGFs have been described and the complexity of this gene family is enhanced by extensive variation in splicing (Jaye et al, 1992) . Each receptor has a similar structure of three extracellular immunoglobulin domains that are involved in ligand binding, a transmembrane domain and an intracellular split tyrosine kinase domain (Jaye et al, 1992) . KGF binds to a splice variant of FGFR-2 (Miki et al, 1991) . Alternative splicing of the carboxyl-terminal half of the third immunoglobulin-like domain changes the ligand-binding properties of FGFR-2 with FGFR-2-IIIb binding to FGF1 and KGF whereas FGFR-2-IIIc binds to FGF1 and FGF2 (Miki et al, 1992; Yayon et al, 1992) . These two isoforms of FGFR-2 appear to be expressed in a mutually exclusive fashion in many cell systems. Cells of mesenchymal origin express FGFR-2-HIc, whereas epithelial cells express FGFR-2-IIIb (Pekonen et al, 1993; Savagner et al, 1994) .
Several studies have examined the expression of FGFs in the malignant and non-malignant breast. mRNA encoding FGF1, FGF2, FGF5, FGF6, FGF7 and FGF9 has been detected in breast cancer, with expression of FGF1 and FGF2 found in all breast cancers whereas the others showed more restricted expression (Penault-Llorca et al, 1995) . Quantitative studies comparing expression levels in malignant and non-malignant breast showed that FGF1 and FGF2 are present in considerable quantities in the non-malignant breast but their expression is greatly reduced in malignant tissues Anandappa et al, 1994; Luqmani et al, 1992) . These results may indicate that FGF1 and FGF2 have a role in maintaining the normal ducts. FGF2 has been localized to the myoepithelial cells of the normal breast by immunocytochemistry but could not be detected in normal or malignant epithelial cells by this technique (Gomm et al, 1991) . High-affinity receptors for FGFs are found in breast cancer cells. Amplification of the FGFR-J and FGFR-2 genes was found in 12.7% and 11.5% of breast tumours respectively and gene amplification of FGFR-4 was found in 10% of breast cancers (Adnane et al 1991 , Jaakkola et al, 1993 . Elevated levels of FGFR mRNAs were found in several breast cancer cell lines (Lehtola et al, 1992; McLeskey et al 1994) . The expression of different splice variants of FGF receptors could also be important in breast cancer and a high ratio of beta to alpha form expression of FGFR-1 has been associated with a reduced disease-free survival in patients with breast cancer .
In this study, we have addressed the issue of whether KGF has a role in the human breast and the development of breast cancer. KGF is an androgen-induced stromal growth factor that can stimulate epithelial growth and morphogenesis in the developing prostate and seminal vesicle (Yan et al, 1992; Alarid et al, 1994) . KGF has also been shown to be a progestomedin in the endometrium of primates (Koji et al, 1994) . Its role in the mammary gland, another steroid hormone-dependent tissue, is less Not known 5 well defined. However, studies in mice have shown that KGF is a mitogen for primary cultures of mammary epithelium (Imagawa et al, 1994) and systemic administration of KGF leads to hyperproliferation of the mammary gland, giving the histological appearance of fibrocystic disease (Yi et al, 1994) . KGF has been linked to human pancreatic cancer with 44% of pancreatic cancer samples showing overexpression of KGF mRNA by Northem analysis (Siddiqi et al, 1995 Figure 1 Southern blot of RT-PCR products for KGF and actin amplified from malignant and non-malignant tissues. RNA (2 jg) from breast tissues was used to make cDNA. KGF and actin PCR products were amplified from aliquots of this cDNA. The products were run on 1.5% agarose gels, blotted onto Hybond N+ membrane and 32P-labelled probes were used to identify and quantify bands. Lanes 1-9 contain PCR products from breast cancer tissues, lanes 10-11 contain PCR products from non-malignant breast tissues blotted onto nitrocellulose. The blot was probed with a ral antibody against KGF and anti-rabbit horseradish peroxic were visualized using ECL reagents
Tissues
Breast tissue obtained at surgery was snap froz liquid nitrogen. We collected cancer tissue from details are given in Table 1 , showing these to be sentative cohort of breast cancer patients with being pre/perimenopausal and 40% having oe:
positive carcinomas. Breast tissue adjacent to ca benign conditions histologically confirmed to t was also collected and is referred to as normal.
Oligonucleotides
Oligonucleotide primers were synthesized on a Cyclone Plus DNA Synthesizer (Milligan Bioresearch, MA, USA). The primers used for the PCR were: for KGF, 5'-ATGGAAATCAGGACAGTGGC-3' (sense) and 5'-CATAGGAAGAAAGTGGCCTG-3' (antisense);
for FGFR-2,5'-CTGGATGTTGTGGAGCGAT-3' (sense) and 5'-TGTAATCTCCTllTTCTCTT CCA-3' (antisense); for actin, 5'-CATCTCTTGCTCGAAGAAGTCCA-3' and 5'-ATCATGTTT-GAGACCTTCAA-3'; for EMA, 5'-TCCGCTCCACCTCT-CAAG-3' (sense) and 5'-CTCACAGCATTCTTCTCAGTAG-3' (antisense); and for CALLA, 5'-TTGTAAGCAGCCTCAGCC-3' (sense) and 5'-TTGTCCACClTTlCTCGG-3' (antisense). The FGFR-2-IIIb PCR product was detected specifically by hybridizing with the 32P-labelled intemal oligonucleotide 5'-TGGGAACTATTTATCCCCG-3' (antisense).
Determination of KGF and FGFR-2-lllb mRNA by RT-PCR amplification Cellular RNA was extracted from pulverized frozen tissues using the guanidiniumisothiocyanate method (Chirgwin et al, 1979) and from the cell lines by the modified RNAzol procedure (Chomczynsky and Saatchi, 1987) . Reverse transcription and PCR amplification was performed as described previously (Luqmani et al, 1992 Hybridization was carried out as described by Church and Gilbert (1984) . We initially used plasmids containing KGF or actin -21.5 kDa cDNA for hybridizations to verify identity and size of PCR products. As single bands were seen, we subsequently used PCR products (made using plasmid template) random primer labelled (Feinberg and Vogelstein, 1983) 
Cell proliferation assay
Approximately 5000 MCF7 or MDA-MB-231 cells in CDM5 medium (DMEM/F-12 containing, 10 nM Hepes, 10 nM L-glutamine, 100 U ml penicillin, 200 mg ml-1 streptomycin, 50 U mlpolymixin B, 2.5 mg ml-1 amphotericin B, insulin 3 mg ml-1, hydrocortisone 0.5 mg ml-1, oestradiol 1 nM, fetuin 20 mg ml-, transferrin 25 mg ml-', phosphoethanolamine 0.1 mM, BSA yoepithelial cells 0.01%, ascorbic acid 10 mg ml-' dibutyryl cAMP 10 nm, sodium amplify sequences selenate 2.6 ng ml-1, triiodothyronine 10 nm, trace element mix elial cell marker 1 ml ml) were seeded into each well of 96-well plates except for aducts were run out the edge wells. One plate was seeded per day of harvest. The cells )ands were viewed were treated with varying concentrations of growth factor in Juct from epithelial CDM5 medium in replicates of six. Cells were incubated for 0-11 niyoepithelial cells days and the number of viable cells in each well was measured using the sulphorhodamine (SRB) assay (Skehan et al, 1990) . Cells were lysed with 50% ice-cold TCA for I h, rinsed with water five times and stained with 0.5% sulphorhodamine red for 1 h, after which the cells were rinsed in 10 mm Tris-HCI pH 7.4 and left to dry overnight. The dye was dissolved by adding 100 gl of 10 mM Tris-HCl pH 7.4 to each well and the optical density at 492 nm of each well was read using a spectrophotometer. 
RESULTS

KGF mRNA expression in breast tissues
KGF protein in breast tissues
The expression of KGF protein was assessed in 20 malignant and non-malignant tissue samples using Western blotting and a representative blot is shown in Figure 3 . The antibody used is specific to KGF and did not cross-react with FGF1 and FGF2 (data not shown). A band of 28 kDa, which we believe corresponds to KGF, was seen in most of the samples. This is slightly larger than the recombinant KGF loaded alongside because of glycosylation, as reported previously (Finch et al, 1995 Figure 4 show that the cell populations were very pure, with EMA mRNA being detected only in epithelial cells and CALLA mRNA being detected only in myoepithelial cells. We find low levels of KGF mRNA in both non-malignant and malignant breast epithelial cells and in myoepithelial cells ( Figure 5 ). Much higher levels of expression are seen in all the fibroblast cell lines examined. Breast fibroblasts purified from reduction mammoplasty material express high levels of KGF mRNA as do MRC5 fetal lung fibroblasts and myoblasts. The low levels of KGF mRNA found in breast epithelial cells may reflect the sensitivity of RT-PCR linked to a Southern blotting detection and may (Luqmani et al, 1996) .
Proliferative effect of KGF on breast cancer cell lines
We wished to investigate whether the level of FGFR-2-IIIb expression in breast cancer cells was sufficient to elicit a growth response after treatment with KGF. A SRB cell proliferation assay was performed to assess the proliferative effect of KGF compared with epidermal growth factor (EGF) on the breast cancer cell lines MCF7 and MDA-MB-231. The cells were seeded into 96-well plates and grown in the serum-free medium CDM5 supplemented with 10 ng mll EGF or 10 ng ml-1 KGF. Cells were harvested and assayed on the same day and at four subsequent time points. As seen in Figure 7 , the growth of both cell lines was slightly stimulated by KGF treatment but not to as great an extent as seen with EGF treatment. (Luqmani et al, 1992; Anandappa et al, 1994; Bansal et al, 1995) . Low levels of FGF2 in breast cancer have been linked to poor prognosis (Yiangou et al, 1996) . FGF3 and FGF4 are not detected in either malignant or non-malignant breast and although FGF5, 6, 7 and 9 have been detected in breast cancer cell lines, no detailed data are available on their levels of expression (Wilson et al, 1994; Penault-Llorca et al, 1995) . Therefore KGF is the first FGF described for which expression is retained at an equivalent level following the onset of malignant breast disease. KGF differs from FGF1 and FGF2 in being expressed in stromal fibroblasts rather than epithelial cells, and this may contribute to its continued expression in breast cancer tissues.
Breast cancer cells express the FGFR-2-IIIb splice variant, which has been identified as a receptor for KGF (Miki et al, 1992) . Our study of FGFR-2-IIIb expression showed no receptor in breast fibroblasts, consistent with a paracrine role for KGF as seen in different tissues (Finch et al, 1989 (Penault-Llorca et al, 1995) . However, using an RT-PCR-based method, FGFR-2 was detectable in 89% of breast tumours (Luqmani et al, 1996) . It is likely that FGFR-2 is present in the majority of breast cancers but at fairly low levels. This raises the issue of whether the observed low levels of FGFR-2 are sufficient to allow KGF stimulation. Our cell proliferation assays revealed that the levels of FGFR-2-IIIb found in breast cancer cells are sufficient to promote KGF-stimulated cell division, although to a lesser extent than EGF. The MCF7 breast cancer cell line, which expresses a higher level of KGF receptor, was stimulated to a greater extent than MDA-MB-231, cells implying that higher receptor expression may lead to a greater proliferative response. We have only examined one aspect of the response of breast cancer cells to KGF stimulation and KGF stimulation may have other consequences such as changing cell motility or invasiveness, which could affect the progression of breast cancer. We have previously reported that there is no significant difference between the level of FGFR-2-IIIb mRNA in non-malignant and malignant breast tissues and that FGFR-2-IIIb is detectable in 89% of breast cancer tissues (Luqmani et al, 1996) . Thus, KGF produced by breast fibroblasts will have no autocrine role but could potentially act on breast epithelial cells in both the normal and malignant breast by a paracrine stimulation.
Like other members of the FGF family, KGF binds to heparinsulphate proteoglycans and would normally bind tightly to the basement membrane that separates the stroma where KGF is synthesized from the epithelial cells, which have receptors that recognize KGF. In invasive breast cancer the basement membrane and myoepithelial cells are no longer present and it is possible that KGF will have greater access to the malignant epithelial cells. If this situation is true, KGF might be expected to stimulate epithelial cells to a greater extent in breast cancer than the normal breast. Further experimentation will be required to test this hypothesis, perhaps by testing whether larger quantities of KGF are released into conditioned medium from breast cancer tissues than from normal breast tissues. KGF is able to stimulate proliferation of breast cancer cells and may have additional effects on cell motility or invasiveness. It has been reported that KGF expression in fibroblasts is induced by serum growth factors and pro-inflammatory cytokines (Brauchle et al, 1994) . These findings suggest that serum factors that are released upon haemorrhage and cytokines released from polymorphonuclear leucocytes and macrophages will induce KGF in vivo. Both of these mechanisms may be active in promoting the expression of KGF in fibroblasts surrounding breast cancers.
Laboratory studies point to the importance of stromal cells in the development and growth of breast cancer. Conditioned media from human breast cancer-derived fibroblasts stimulate the growth of breast cancer cells (van Roozendaal et al, 1992; Ryan et al, 1993; Singer et al, 1995) . Co-culture experiments in which breast cancer cells and fibroblasts are separated by a microporous membrane have shown that factors secreted by fibroblasts stimulate the growth of breast cancer cells with reciprocal stimulation of fibroblast growth by the breast cancer cells (Hofland et al, 1995) . The growth factors involved in this phenomenon are not well characterized; however, their effect is additive with that of insulin, EGF and even serum (Hofland et al, 1995) . This suggests that factors involved will be different to these. Insulin-like growth factor II expression is increased in fibroblasts surrounding breast tumours and is able to stimulate the growth of breast cancer cells, making it a possible candidate as a paracrine growth factor affecting breast cancer progression. However, other growth factors such as KGF may also be involved (Singer et al, 1995; Cullen et al, 1992) .
KGF is the first member of the FGF family to be found at similar levels in breast cancers and non-malignant breast tissues. It is expressed in stromal fibroblasts and is capable of stimulating cell proliferation of breast cancer cells in which expression of FGFR-2-IIIb appears to be retained. The loss of the basement membrane and myoepithelial cells in invasive breast cancer may lead to greater access of KGF to the breast cancer cells. These results suggest that further studies may be worthwhile in order to investigate a possible paracrine role for KGF in breast cancer.
